FDA APPROVED
IS THE TIME TO PREVENT INTRAOPERATIVE MIOSIS
AND REDUCE POSTOPERATIVE OCULAR PAIN
OMIDRIA
™
(phenylephrine and ketorolac injection) 1% / 0.3%
is the fi rst and only FDA-approved treatment that both
1
:
Preemptively inhibits intraoperative miosis
Decreases postoperative ocular pain for 10 to 12 hours
OMIDRIA is preservative- and bisulfi te-free
1
OMIDRIA requires no change to routine operating procedures
1
INDICATION AND USAGE
OMIDRIA is an 1-adrenergic receptor agonist and nonselective
cyclooxygenase inhibitor indicated for:
Maintaining pupil size by preventing intraoperative miosis
Reducing postoperative ocular pain
OMIDRIA is added to an irrigation solution used during cataract
surgery or intraocular lens replacement.
